Trastuzumab and trastuzumab deruxtecan used as the standard-of-care in human epidermal growth factor receptor 2 (HER2)-positive gastric cancer, which accounts for 20% of all gastric cancers2,3. This evidence concerns the gene ERBB2 and gastric cancer.